Home » Newsletters » The Carlat Child Psychiatry Report

The Carlat Child Psychiatry Report

Catatonia in Children and Adolescents (Oct/Nov/Dec) | 2022

View Archived Issues

Learning Objectives, Catatonia in Children and Adolescents, CCPR, Oct/Nov/Dec 2022

October 1, 2022

After reading these articles, you should be able to…

Note From the Editor-in-Chief

October 1, 2022

Joshua Feder, MD

If your practice is like mine, things are chaotic for our kids returning to school this fall after two distressing years. Diagnosis is more complicated, so for this issue we picked subjects that can expand your diagnostic acumen.

Bipolar Spectrum Disorders in Children and Adolescents

October 30, 2022

Bipolar disorder is challenging to diagnose in children and adolescents, yet timely and accurate diagnosis is crucial.

Assessing and Treating Catatonia in Children and Adolescents

October 1, 2022

Lee Wachtel MD

Catatonia is marked by a change from the person’s baseline state with distinct motor, vocal, and behavioral symptoms. Clinicians usually think of a catatonic person as being like a statue—immobile, unresponsive, staring, and with waxy flexibility.

Assessing Sensory Processing Challenges

October 1, 2022

Virginia Spielmann PhD and Sarah A Schoen PhD, OTR/L

Learn to identify sensory challenges to address these barriers to effective care in teens and adolescents.

Consider Catatonia in Your Differential

October 1, 2022

John Raiss, MD

Catatonia is common in adult inpatient settings, where 6%–15% meet diagnostic criteria. In children and adolescents, prevalence estimates vary more widely, from 0.6% to 17%, perhaps because catatonia is often misdiagnosed or unrecognized. Like delirium, catatonia occurs as part of many conditions, including psychosis, mood disorders, substance use, autistic spectrum disorder, and medical conditions.

SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?

October 1, 2022

Joshua Feder, MD

Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID.